 | In a letter to the Institute for Clinical and Economic Review (ICER), the Partnership to Improve Patient Care (PIPC) offered comments on ICER's assessment of KarXT for schizophrenia. |
The letter is critical of ICER's assessment for its use of the EQ-5D tool, which is known to be insensitive to changes in quality of life for psychiatric conditions. PIPC also encourages ICER to move away from the assumption that all patients are "average."
"If ICER is to take seriously its role of informing health policy decision makers about the value of new therapies, it needs to move away from the assumption that all patients are the same, and the value to each can be determined by the estimation of the average value to a patient archetype," wrote PIPC Chair Tony Coelho. "PIPC urges ICER to reconsider some of its modeling choices to ensure it is providing an accurate picture of value to the patient and society."
"If ICER is to take seriously its role of informing health policy decision makers about the value of new therapies, it needs to move away from the assumption that all patients are the same, and the value to each can be determined by the estimation of the average value to a patient archetype," wrote PIPC Chair Tony Coelho. "PIPC urges ICER to reconsider some of its modeling choices to ensure it is providing an accurate picture of value to the patient and society."
| icer_schizofrenia_final.pdf |
